Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.21M | -2.27M | -1.05M | -3.55M | -3.55M |
| Total Depreciation and Amortization | 1.70K | 1.20K | 700.00 | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.23M | -166.30K | -1.27M | -- | -- |
| Change in Net Operating Assets | -6.98M | -7.28M | -7.01M | 2.10M | 2.10M |
| Cash from Operations | -9.96M | -9.72M | -9.32M | -1.45M | -1.45M |
| Capital Expenditure | -13.10K | -13.10K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -775.00K | -1.33M | -2.13M | -2.85M | -2.85M |
| Cash from Investing | -788.10K | -1.34M | -2.13M | -2.85M | -3.55M |
| Total Debt Issued | 4.34M | 5.04M | 6.02M | 3.92M | 3.92M |
| Total Debt Repaid | -1.30M | -1.30M | -1.30M | -- | -- |
| Issuance of Common Stock | 10.56M | 10.56M | 10.56M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.56M | -2.56M | -2.53M | 0.00 | 0.00 |
| Cash from Financing | 11.03M | 11.73M | 12.75M | 3.92M | 5.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 281.40K | 677.50K | 1.30M | -378.10K | -786.10K |